Apolipoprotein M in patients with chronic kidney disease
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › fagfællebedømt
Standard
Apolipoprotein M in patients with chronic kidney disease. / Sørensen, Ida MH; Bertelsen, Marianne; Freese, Ellen; Lindhard, Kristine; Ullum, Henrik; Feldt-Rasmussen, Bo; Nielsen, Lars Bo; Christoffersen, Christina; Bro, Susanne.
I: Atherosclerosis, Bind 275, 2018, s. 304-311.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Apolipoprotein M in patients with chronic kidney disease
AU - Sørensen, Ida MH
AU - Bertelsen, Marianne
AU - Freese, Ellen
AU - Lindhard, Kristine
AU - Ullum, Henrik
AU - Feldt-Rasmussen, Bo
AU - Nielsen, Lars Bo
AU - Christoffersen, Christina
AU - Bro, Susanne
PY - 2018
Y1 - 2018
N2 - Background and aims: Plasma apolipoprotein M (APOM) is bound to HDL-particles and has anti-atherogenic effects. The present study explored whether plasma APOM is reduced in patients with chronic kidney disease (CKD), and associated with cardiovascular disease (CVD). In addition, we tested the hypothesis that the excretion of APOM into the urine is increased in patients with kidney disease. Methods: Plasma samples were collected from a cohort of patients with CKD stages 1 to 5D (N = 409) and controls (N = 35). Urine was collected from 47 subjects. Plasma APOM was measured with sandwich ELISA and urine APOM with competitive ELISA. Results: Plasma APOM levels were reduced in patients with CKD stages 3-5D as compared to patients with CKD stages 1 + 2 and controls (p < 0.01). CKD patients with known CVD displayed even further reduction in plasma APOM levels than CKD patients without known CVD (p < 0.001). Fast-phase liquid chromatography showed that plasma APOM was primarily associated with HDL-cholesterol (HDL-C) across CKD stages. Accordingly, when plasma APOM values were corrected for HDL-C, a significant difference only persisted between patients with CKD stage 3 and stages 1 + 2 (p < 0.05), and the difference between CKD patients with and without known CVD disappeared. Urine APOM/creatinine ratio was not significantly increased in patients with kidney disease. Conclusions: The results show that the difference in plasma APOM levels observed between patients with mild and advanced CKD may mainly be due to differences in plasma HDL-C. Whether APOM plays a role in human uremic atherogenesis warrants further experimental studies.
AB - Background and aims: Plasma apolipoprotein M (APOM) is bound to HDL-particles and has anti-atherogenic effects. The present study explored whether plasma APOM is reduced in patients with chronic kidney disease (CKD), and associated with cardiovascular disease (CVD). In addition, we tested the hypothesis that the excretion of APOM into the urine is increased in patients with kidney disease. Methods: Plasma samples were collected from a cohort of patients with CKD stages 1 to 5D (N = 409) and controls (N = 35). Urine was collected from 47 subjects. Plasma APOM was measured with sandwich ELISA and urine APOM with competitive ELISA. Results: Plasma APOM levels were reduced in patients with CKD stages 3-5D as compared to patients with CKD stages 1 + 2 and controls (p < 0.01). CKD patients with known CVD displayed even further reduction in plasma APOM levels than CKD patients without known CVD (p < 0.001). Fast-phase liquid chromatography showed that plasma APOM was primarily associated with HDL-cholesterol (HDL-C) across CKD stages. Accordingly, when plasma APOM values were corrected for HDL-C, a significant difference only persisted between patients with CKD stage 3 and stages 1 + 2 (p < 0.05), and the difference between CKD patients with and without known CVD disappeared. Urine APOM/creatinine ratio was not significantly increased in patients with kidney disease. Conclusions: The results show that the difference in plasma APOM levels observed between patients with mild and advanced CKD may mainly be due to differences in plasma HDL-C. Whether APOM plays a role in human uremic atherogenesis warrants further experimental studies.
KW - Cardiovascular risk
KW - Chronic kidney disease
KW - HDL cholesterol
KW - LDL-cholesterol
KW - Plasma apolipoprotein M
KW - Urine apolipoprotein M sphingosine-1-phosphate
U2 - 10.1016/j.atherosclerosis.2018.06.815
DO - 10.1016/j.atherosclerosis.2018.06.815
M3 - Journal article
C2 - 29980057
AN - SCOPUS:85049320575
VL - 275
SP - 304
EP - 311
JO - Atherosclerosis
JF - Atherosclerosis
SN - 0021-9150
ER -
ID: 200338738